Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07605429 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Study sites: 2 to 3 Start date changed from estimate of Jun 2026 to Jun 23, 2026v4 Show 1 more changeShow less
    • Start date changed from estimate of Jun 2026 to Jun 23, 2026
  3. Recruitment opened Study sites: 0 to 2v3 Show 1 more changeShow less
    • Study sites: 0 to 2
  4. Interventions: Sham Control (Procedure), rugonersen (Drug) to Sham procedure (Procedure), rugonersen (Drug) Secondary endpoints: details revised at 1 of 3 entries · Study title expanded, about 2 wordsv2 Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 3 entries
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Purpose of the study is to evaluate the efficacy and safety of intrathecally administered rugonersen in pediatric and adult participants with Angelman syndrome.
Trial Details
NCT Number NCT07605429
Lead Sponsor OHB Pediatrics Ltd.
Collaborators: Medpace, Inc.
Conditions Angelman Syndrome
Enrollment 165 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov